Dr. Elyse Watkins
Doxorubicin, one of the most commonly used anthracycline chemotherapy agents, is known in the oncology field for potential cardiotoxicity. The purpose of this article is to present a case of a breast cancer patient who was treated with an anthracycline chemotherapy agent and presented with newly diagnosed cardiomyopathy. The article will review the workup leading to the diagnosis of anthracycline cardiotoxicity, mechanisms of action, and proposed management.
DeJesus N. Cardiotoxicity after Breast Cancer: A Case Study and Review of Anthracycline Cardiomyopathy. Lynchburg Journal of Medical Science. 2022; 4(3).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.